Result card

  • TEC8: What is the place and context for utilising FEMTELLE®, MammaPrint®, and Oncotype DX™?
Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX )
B0005
English
No adaptation help available for this domain

What is the place and context for utilising FEMTELLE®, MammaPrint®, and Oncotype DX™?

Authors: Pseudo169 Pseudo169, Pseudo90 Pseudo90, Pseudo154 Pseudo154, Pseudo98 Pseudo98

Internal reviewers: Patricia Harrington, Michelle O'Neill, Leonor Varela

The manufacturer’s website and direct questions to manufacturers were used to develop this assessment element.

The three tests (FEMTELLE, MammaPrint, and Oncotype DX) are add-on tests (not replacing any existing tests) to provide additional information in the tertiary care setting (i.e. specialised consultative healthcare facilities). The tissue samples are collected during breast cancer surgery. The information provided by the tests will be used by the multidisciplinary cancer team to supplement the other clinical and pathological information to determine whether or not the patient should receive adjuvant therapy.

Critical
Completely
Pseudo169 P et al. Result Card TEC8 In: Pseudo169 P et al. Description and technical characteristics of technology In: Jefferson T, Vicari N, Raatz H [eds.]. Prognostic tests for breast cancer recurrence (uPA/PAI-1 [FEMTELLE], MammaPrint, Oncotype DX ) [Core HTA], Agenzia nationale per i servizi sanitari regionali (age.na.s), Italy ; 2013. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=113